Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Slides:

Advertisements

Similar presentations

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,

Advertisements

Palumbo A et al. Proc ASH 2012;Abstract 446.

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome by Annamaria Brioli, Hannah Giles,

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Mark TM et al. Proc ASH 2012;Abstract 77.

First-Line Treatment for MM Patients Ruben Niesvizky Department of Medicine, Division of Hematology/Oncology, Weill-Cornell Medical College / New York.

Pomalidomide + Low-Dose Dexamethasone (POM + LoDex) vs High-Dose Dexamethasone (HiDex) in Relapsed/Refractory Multiple Myeloma (RRMM): MM-003 Analysis.

Pomalidomide Plus Low-Dose Dex vs High-Dose Dex in Rel/Ref Myeloma

Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.

San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.

Smoldering Myeloma: To Treat or not to Treat

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

Relapsed Refractory Myeloma: The Case for Single Agent Approach

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Rossi A et al. Proc ASCO 2011;Abstract 8008.

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.

Transplants for the elderly in myeloma

How I treat elderly patients with myeloma

Nonmyeloablative conditioning for relapsed follicular lymphoma

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

A phase 2 study of single-agent carfilzomib (PX A1) in patients with relapsed and refractory multiple myeloma by David S. Siegel, Thomas Martin,

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma by Paul G. Richardson, Wanling.

by Sabah Sallah, and Jim Y. Wan

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

Imatinib for refractory chronic graft-versus-host disease with fibrotic features by Attilio Olivieri, Franco Locatelli, Marco Zecca, Adele Sanna, Michele.

Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma by Kay.

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group.

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma Tomer.

Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.

Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD by Gérard Socié, Noel Milpied, Ibrahim.

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB (Alliance)‏ by John C. Byrd, Amy S. Ruppert,

A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Dharshan Sivaraj, Michael.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory.

Boccadoro M et al. Proc ASCO 2011;Abstract 8020.

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma by Matthew J. Matasar, Myron S. Czuczman,

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma by Tineke Casneuf, Xu Steven.

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma by Sham Mailankody, Dickran Kazandjian, Neha Korde,

Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients by Cirino Botta, Domenico Ciliberto,

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,

by Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A

Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients by Jenna Sopfe, Laura Pyle, Amy K.

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.

Treatment options for relapsed and refractory multiple myeloma

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma.

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study by Guillermo Garcia-Manero, Yasmin.

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary.

Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study by Xiao-Qi Qin, Gang An, Zeng-Jun.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma by Maximilian Merz, Anna Jauch, Thomas Hielscher,

External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation by Roni Shouval, Joshua A. Fein,

by Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J

Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.

Presentation transcript:

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana C. Rossi, Roger N. Pearse, Karen A. Pekle, Arthur Perry, Angelique Boyer, Linda Tegnestam, David Jayabalan, Morton Coleman, and Ruben Niesvizky BloodAdv Volume 3(4):603-611 February 26, 2019 © 2019 by The American Society of Hematology

Tomer M. Mark et al. Blood Adv 2019;3:603-611 © 2019 by The American Society of Hematology

Responses over time to ClaPD. Responses over time to ClaPD. Responses by treatment cycle in patients who were lenalidomide refractory (A), bortezomib refractory (B), and refractory to both lenalidomide and bortezomib (double refractory) (C). Tomer M. Mark et al. Blood Adv 2019;3:603-611 © 2019 by The American Society of Hematology

Survival outcomes. Survival outcomes. (A) PFS. Median PFS was 7.67 months (95% CI, 5.6, 9.5). (B) OS. Median OS was 19.2 months (95% CI, 14.2, 26.7). Tomer M. Mark et al. Blood Adv 2019;3:603-611 © 2019 by The American Society of Hematology